Blog
39 Articles
![Cover image for Treatments and Clinical trials webinar](https://letswinpc.org/wp-content/uploads/2023/11/webinar-treatments-clinical-trials-8nov2023.jpg)
Treatments and the Importance of Clinical Trials
In a webinar, Drs. Allyson Ocean and Arturo Loaiza-Bonilla discuss pancreatic cancer treatments and why clinical trials are so important.
![yellow orange lines against a black background](https://letswinpc.org/wp-content/uploads/2023/05/piezoresponse.jpg)
Adapting Chemotherapy Regimens for a Better Pancreatic Cancer Outcome
Researchers are comparing chemotherapy regimens for effectiveness before surgery, and whether switching treatments makes a difference.
![Dr. Marco Del Chiaro, pancreatic cancer surgeon](https://letswinpc.org/wp-content/uploads/2023/05/Del_Chiaro_Marco-horiz.jpg)
New Study Shows Benefit of Chemotherapy after Surgery
Should you have adjuvant chemotherapy–treatment after pancreatic cancer surgery? Dr. Marco Del Chiaro explains that the evidence says “yes.”
![molecule model made of silvery beads on a yellowish background](https://letswinpc.org/wp-content/uploads/2023/03/beaded-molecule.jpg)
Comparing Chemotherapy Before with Chemotherapy After Pancreatic Cancer Surgery
Researchers are comparing effectiveness of chemotherapy before surgery (neoadjuvant) with chemotherapy after surgery (adjuvant).
![Dr. Matthew Katz](https://letswinpc.org/wp-content/uploads/2022/08/Matthew-Katz-Md-v2.jpg)
Shedding More Light On Neoadjuvant Treatment
Dr. Matthew Katz reviews the study that compared neoadjuvant treatment with FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic cancer.
![Susan Tsai](https://letswinpc.org/wp-content/uploads/2022/06/Susan-Tsai-border.jpg)
Access and Disparities in Pancreatic Cancer Surgery Remain Pervasive Problems
Dr. Susan Tsai discusses her research into the causes of pancreatic cancer surgery and treatment disparities for underserved communities.
![Kim Reiss Binder](https://letswinpc.org/wp-content/uploads/2022/10/Kim-Reiss-Binder.jpg)
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
![Dr. Matthew Katz](https://letswinpc.org/wp-content/uploads/2022/10/Matthew-Katz-Md.jpg)
New Data Support Preoperative Chemoradiation Regimen for Borderline Resectable Pancreatic Cancer
Should patients get chemotherapy or chemoradiation before surgery? Dr. Matthew Katz provides an update on the Alliance study.
![](https://letswinpc.org/wp-content/uploads/2022/09/ct2021apr5.jpg)
Adaptive Pre-Surgery Therapy for Patients with Localized Pancreatic Cancer
Will a flexible approach to neoadjuvant treatment work better for pancreatic cancer patients with tumors that can be removed surgically?
![Doctor talking to a patient in a hospital bed](https://letswinpc.org/wp-content/uploads/2022/08/mpc2021mar5.jpg)
The Pancreatic Standard of Care is No Longer So Standard
Do you want to understand more about how your doctor chooses your treatments? Learn about the standard of care for pancreatic cancer.